Nick Nissen

Phase I trial of Bermekimab with nanoliposomal irinotecan and 5-fluorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma

M. Tighiouart, Julianne C. Yang, J. Gong, 2022, Scientific Reports.

Early Application of Next-Generation Sequencing Identifies Pancreatic Mass as Metastasis From an EGFR-Mutated Lung Adenocarcinoma.

J. Gong, S. Gaddam, A. Hendifar, 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

Pancreatic Cancer Incidence Trends by Race, Ethnicity, Age and Sex in the United States: A Population-Based Study, 2000–2018

S. Lo, Debiao Li, S. Pandol, 2023, Cancers.

Increasing Pancreatic Cancer Incidence in Young Women in the US: A Population-Based Time-Trend Analysis, 2001-2018.

S. Lo, Debiao Li, Shirley C. Paski, 2023, Gastroenterology.

Recent advances in the management of hepatocellular carcinoma.

J. Gong, A. Hendifar, A. Osipov, 2023, Clinical and molecular hepatology.

Successful treatment of acute antibody-mediated rejection of liver allograft with imlifidase: A case report

T. Todo, S. Jordan, G. Voidonikolas, 2023, Transplantation Reports.

A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer

S. Piantadosi, H. Sandler, S. Lo, 2019, EBioMedicine.

Patterns of Failure in Patients With Borderline Resectable/Locally Advanced Pancreatic Cancer After Preoperative Chemotherapy and Stereotactic Body Radiation Therapy

A. Gangi, A. Hendifar, A. Osipov, 2024, Advances in Radiation Oncology.

5-Hydroxymethylcytosine (5-hmC) loss is a marker of malignancy in biliary neoplasms.

A. Hendifar, A. Osipov, K. Kosari, 2024, American journal of clinical pathology.